Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild Type mCRC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07490119
What this trial is testing

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Who this might be right for
RAS Wild Type mCRC
Fudan University 31
Testing effectiveness (Phase 2)Looking for participantsNCT06776757
What this trial is testing

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 30
Not applicableStudy completedNCT03043950
What this trial is testing

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

Who this might be right for
Metastatic Colorectal CancerRAS Wild-type
iOMEDICO AG 647
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Testing effectiveness (Phase 2)Study completedNCT04561336
What this trial is testing

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal CancerRAS Wild Type
University of Campania Luigi Vanvitelli 77
Large-scale testing (Phase 3)Study completedNCT04835142
What this trial is testing

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Who this might be right for
Metastatic Colorectal Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 688
Testing effectiveness (Phase 2)UnknownNCT05278351
What this trial is testing

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Who this might be right for
Colorectal Neoplasms Malignant
Shanghai Zhongshan Hospital 87
Testing effectiveness (Phase 2)Study completedNCT04080843
What this trial is testing

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

Who this might be right for
Colorectal CancerRAS and BRAF Wild-typeColorectal Neoplasms+10 more
Zhejiang University 30
Testing effectiveness (Phase 2)UnknownNCT06379399
What this trial is testing

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Who this might be right for
Colorectal Cancer Metastatic
Wangxia LV 26
Not applicableStudy completedNCT04757311
What this trial is testing

Metastatic Colorectal Cancer. Real-World Data Analysis.

Who this might be right for
Metastatic Colorectal Cancer
Istanbul Medeniyet University 1,750
Not applicableStudy completedNCT02792478
What this trial is testing

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

Who this might be right for
RAS Wild Type mCRC
Amgen 238